Recombinant FVIII-Fc fusion protein (Chengdu Rongsheng)
- Generic Name
- Recombinant FVIII-Fc fusion protein (Chengdu Rongsheng)
Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein
- First Posted Date
- 2023-11-21
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Jiangsu Gensciences lnc.
- Target Recruit Count
- 120
- Registration Number
- NCT06142552
- Locations
- 🇨🇳
The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
🇨🇳Fujian Medical University Union Hospital, Fuzhou, China
🇨🇳Anhui Provincial Hospital, Hefei, China
A Study of Repeat Dosing of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection
- First Posted Date
- 2022-03-03
- Last Posted Date
- 2023-05-15
- Lead Sponsor
- Jiangsu Gensciences lnc.
- Target Recruit Count
- 15
- Registration Number
- NCT05265286
- Locations
- 🇨🇳
People'S Hospital of Zhengzhou, Zhengzhou, Henan, China
🇨🇳Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, China
🇨🇳The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
A Study to Evaluate the Pharmacokinetics，Safety and Tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection
- First Posted Date
- 2021-04-29
- Last Posted Date
- 2023-09-08
- Lead Sponsor
- Jiangsu Gensciences lnc.
- Target Recruit Count
- 13
- Registration Number
- NCT04864743
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College., Tianjin, Tianjin, China
🇨🇳Nanfang Hospital of Southern Medical University, Guangzhou, Guangzhou, China
🇨🇳Jinan central hospital, Jinan, Shandong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.